Symptoms to watch for

One of the most important details in the FDA's warning is that NAION can develop without pain. Patients may notice a sudden change in vision, sometimes when they wake up in the morning.

Symptoms identified by the regulator include blurred vision, blind spots, tunnel vision, distorted colours and reduced sharpness of sight. The condition typically affects one eye.

The FDA advises patients experiencing these symptoms to contact a healthcare professional immediately. Doctors are advised to arrange a prompt assessment by an ophthalmologist if NAION is suspected.

Stop taking Ozempic or Wegovy?

The FDA has not recommended that everyone taking GLP-1 medicines stop treatment. Instead, it is requiring manufacturers to update their safety information so patients and doctors can make informed decisions.

Patients who develop NAION should discuss whether to continue treatment with their doctor. The FDA advises healthcare professionals to consider discontinuing the medicine if NAION develops, unless the treatment benefits clearly outweigh the risks.

The warning also matters because some patients taking these medicines already have conditions associated with NAION. The FDA identifies diabetes, high blood pressure, smoking, sleep apnoea, anaemia and kidney disease among potential risk factors.

What prompted the FDA's decision?

The investigation began after a study published in July 2024 raised concerns about a possible association between semaglutide and NAION.

The FDA subsequently examined clinical trial results, observational studies, animal research and reports submitted through its adverse-event monitoring system.

Its analysis covered 126 randomised clinical trials involving 134,253 patients. Researchers identified 15 probable NAION cases, including 10 among GLP-1 users and five among patients receiving a placebo.

The regulator calculated incidence rates of 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 cases in the comparison group.

The FDA also conducted a separate real-world study involving patients with type 2 diabetes. That analysis found a statistically significant increase in NAION risk when GLP-1 medicines were compared with one category of diabetes treatments, but not when compared with another.

The agency said its animal research did not identify a mechanism explaining how GLP-1 medicines might increase the risk.

What do the drugmakers say?

Novo Nordisk, which manufactures Ozempic and Wegovy, maintains that the available evidence does not establish a cause-and-effect relationship between GLP-1 medicines and NAION.

The company said it remains confident in the benefit-risk profile of its medicines.

Eli Lilly, which makes Mounjaro and Zepbound, said the FDA's communication applies to the wider GLP-1 medicine category and does not identify findings specific to its products. The company said it was evaluating the regulatory update.

For people currently receiving treatment, the FDA's message is therefore one of awareness rather than a blanket recommendation to discontinue medication. The reported complication remains rare, but sudden changes in eyesight require immediate medical attention.

The new US labelling requirement does not itself establish a change to prescribing rules in the UAE. It does give patients taking these medicines another safety issue to discuss with their treating doctors.

Justin is a personal finance author and seasoned business journalist with over a decade of experience. He makes it his mission to break down complex financial topics and make them clear, relatable, and relevant—helping everyday readers navigate today’s economy with confidence. Before returning to his Middle Eastern roots, where he was born and raised, Justin worked as a Business Correspondent at Reuters, reporting on equities and economic trends across both the Middle East and Asia-Pacific regions.